Under the terms of the J&J deal, Isomorphic will be responsible for in silico predictions and design, while the US group will ...

G protein-coupled receptors (GPCRs) represent the largest family of membrane proteins and one of the most successful therapeutic targets in modern medicine, with approximately 34% of FDA-approved ...

The collaboration marks a turning point in AI-driven drug design and trial forecasting, de-risking the drug development ...

Artificial intelligence (AI)-based drug developer Isomorphic Labs said it has raised $600 million in its first external funding round, with the proceeds expected to accelerate its research and ...

TOKYO--(BUSINESS WIRE)--Elix, Inc. (CEO: Shinya Yuki / Headquarters: Tokyo; hereinafter “Elix”) is pleased to announce that its AI drug discovery platform, Elix ...

Nimbus and Eli Lilly collaborate to develop an oral treatment for obesity, leveraging computational chemistry and structure-based drug design. Nimbus Therapeutics and Eli Lilly announce their ...

This process is costly, time-consuming, and has a low success rate. KAIST researchers have developed an AI model that, using only information about the target protein, can design optimal drug ...

A recent study shows that computer algorithms can be used to find molecules that can be developed into anti-inflammatory drugs. In the article, the researchers also describe how the same strategy can ...

Nimbus Therapeutics announced it has entered into a multi-year research collaboration and $1.3 exclusive license agreement ...

The most familiar artificial intelligence (AI) applications include text generation, facial recognition, and autonomous driving. But there are other AI applications that deserve their share of ...

Dr. Khaled Elokely specializes in the integration of computational and medicinal chemistry for innovative drug design and development at the University of Wyoming. With a background in pharmaceutical ...